Compare Gilead Sciences, Inc. (GILD) vs Hilton Hotels Corporation Common Stock (HLT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Hilton Hotels Corporation Common Stock — how do they compare? Gilead Sciences, Inc. trades at $134.76 (market cap $163.51B), while Hilton Hotels Corporation Common Stock trades at $323.12 (market cap $74.78B). The key difference: Gilead Sciences, Inc. is far larger — about 2.2× Hilton Hotels Corporation Common Stock's market cap, and Gilead Sciences, Inc. pays the higher dividend (2.49%). Which is the better fit depends on your goals.
| GILD | HLT | |
|---|---|---|
Market Cap | $163.51B | $74.78B |
Sector | Health | Consumer Cyclical |
52-Week High | $155.80 | $350.22 |
52-Week Low | $108.22 | $256.75 |
Enterprise Value | $178.05B | $87.27B |
Dividend Yield | 2.49% | 0.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
Hilton Worldwide (HLT) trades at $325.86, showing stability with no recent price change. The stock exhibits bearish technical signals but maintains strong fundamentals, including consistent revenue growth to $12.04B in 2025 and a net income margin of 12.56%. Recent earnings have consistently beaten expectations, and analyst sentiment remains positive with a 55.1% buy rating. Key developments include brand expansions and partnerships, such as the launch of Undergraduate by Hilton and collaborations with Big Brothers Big Sisters, highlighting ongoing growth initiatives.
The outlook for HLT is cautiously optimistic, driven by solid earnings performance and strategic growth, though elevated debt levels and bearish technical indicators pose risks. Investors should weigh the company's strong market position against potential volatility from macroeconomic factors and competitive pressures in the hospitality sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Hilton Hotels Corporation Common Stock
Hilton Worldwide Holdings operates 1,074,791 rooms across its 18 brands addressing the midscale through luxury segments as of Dec. 31, 2021. Hampton and Hilton are the two largest brands by total room count at 28% and 21%, respectively, as of Dec. 31, 2021. Recent brands launched over the last few years include Home2, Curio, Canopy, Tru, and Tempo. Managed and franchised represent the vast majority of adjusted EBITDA, predominantly from the Americas regions.
Read more on HLT →
